Authors' Affiliations: Department of Urology, Union Hospital; Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Cancer Biology Program, Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and Department of Neurology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Georgia Regents University, Augusta, Georgia.
Authors' Affiliations: Department of Urology, Union Hospital; Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Cancer Biology Program, Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and Department of Neurology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Georgia Regents University, Augusta, Georgia
Clin Cancer Res. 2014 May 15;20(10):2617-30. doi: 10.1158/1078-0432.CCR-13-3224. Epub 2014 Mar 19.
Although microRNAs (miRNA) have been revealed as crucial modulators of tumorigenesis, our understanding of their roles in renal cell carcinoma (RCC) is limited. Here we sought to identify human miRNAs that act as key regulators of renal carcinogenesis.
We performed microarray-based miRNA profiling of clear cell RCC (ccRCC) and adjacent normal tissues and then explored the roles of miR-141 both in vitro and in vivo, which was the most significantly downregulated in ccRCC tissues.
A total of 74 miRNAs were dysregulated in ccRCC compared with normal tissues. miR-141 was remarkably downregulated in 92.6% (63/68) ccRCC tissues and would serve as a promising biomarker for discriminating ccRCC from normal tissues with an area under the receiver operating characteristics curve of 0.93. Overexpression of miR-141 robustly impaired ccRCC cell migratory and invasive properties and suppressed cell proliferation by arresting cells at G0-G1 phase in vitro and in human RCC orthotopic xenografts. Significantly, the antitumor activities of miR-141 were mediated by its reversal regulation of erythropoietin-producing hepatocellular (Eph) A2 (EphA2), which then relayed a signaling transduction cascade to attenuate the functions of focal adhesion kinase (FAK), AKT, and MMP2/9. In addition, a specific and inverse correlation between miR-141 and EphA2 expression was obtained in human ccRCC samples. Finally, miR-141 could be secreted from the ccRCC donor cells, and be taken up and function moderately in the ccRCC recipient cells.
miR-141 serves as a potential biomarker for discriminating ccRCC from normal tissues and a crucial suppressor of ccRCC cell proliferation and metastasis by modulating the EphA2/p-FAK/p-AKT/MMPs signaling cascade.
尽管 microRNAs(miRNA)已被揭示为肿瘤发生的关键调节因子,但我们对其在肾细胞癌(RCC)中的作用的理解有限。在这里,我们试图确定作为肾发生关键调节因子的人类 miRNA。
我们对透明细胞肾细胞癌(ccRCC)和相邻正常组织进行了基于微阵列的 miRNA 谱分析,然后探讨了 miR-141 在体外和体内的作用,miR-141 在 ccRCC 组织中下调最为显著。
与正常组织相比,ccRCC 中有 74 个 miRNA 失调。miR-141 在 92.6%(63/68)的 ccRCC 组织中显著下调,可作为区分 ccRCC 与正常组织的有前途的生物标志物,其受体操作特征曲线下面积为 0.93。miR-141 的过表达可显著损害 ccRCC 细胞的迁移和侵袭特性,并通过将细胞阻滞在 G0-G1 期来抑制细胞增殖在体外和人 RCC 原位异种移植中。重要的是,miR-141 的抗肿瘤活性是通过其对红细胞生成素产生肝细胞(Eph)A2(EphA2)的逆转调节介导的,EphA2 然后传递信号转导级联反应,减弱粘着斑激酶(FAK)、AKT 和 MMP2/9 的功能。此外,在人 ccRCC 样本中获得了 miR-141 与 EphA2 表达之间的特异性和反向相关性。最后,miR-141 可以从 ccRCC 供体细胞中分泌出来,并在 ccRCC 受体细胞中被摄取并发挥适度的功能。
miR-141 可作为区分 ccRCC 与正常组织的潜在生物标志物,通过调节 EphA2/p-FAK/p-AKT/MMPs 信号级联反应,成为 ccRCC 细胞增殖和转移的关键抑制因子。